NCT02206035View on ClinicalTrials.gov

A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Hematopoietic Stem Cell Transplantation
Interventions
DRUG

Tacrolimus

Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant.

DRUG

Methotrexate

Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m\^2 Days +3, +6 and +11.

DRUG

Tocilizumab

Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1.

Trial Locations (1)

53226

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

William R. Drobyski, MD

OTHER

NCT02206035 - A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant | Biotech Hunter | Biotech Hunter